Everest Medicines receives China approval for 100 mg eravacycline injection
November 13, 2026
Source: drugdu
26
On November 13, Everest Medicines (01952) announced that China’s drug regulator had approved a new 100 mg strength of its eravacycline hydrochloride for injection. The 50 mg strength was approved in China in 2023 for complicated intra-abdominal infections in adults. The company expects the new strength to give clinicians more preparation options and reduce handling and waste.
Eravacycline is a fully synthetic broad-spectrum fluorocycline antibiotic. Everest has obtained a manufacturing license for its Jiashan site and is moving ahead with local production in China.
Source: http://finance.eastmoney.com/a/202611133930417557.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- GSK’s application for marketing approval in China for its recombinant herpes zoster vaccine pre-filled syringe formulation has been accepted. November 13, 2026
- Novo Nordisk has submitted an application for marketing approval in China for its once-weekly subcutaneous injection of CagriSema, for long-term weight management. November 13, 2026
- Colombia’s INVIMA approves Sinotherapeutics’ generic posaconazole delayed-release tablets November 13, 2026
- Sansure Biotech receives China registration for a liver cancer diagnostic kit November 13, 2026
- Baheal renames itself as it expands into drug development and manufacturing November 13, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
